On November 21, 2022 Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, reported that four abstracts highlighting CFI-402257 and CFI-400945, the Company’s potent and selective inhibitors of TTK and PLK4, respectively, have been accepted for presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas (Press release, Treadwell Therapeutics, NOV 21, 2022, View Source [SID1234624276]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO. "We look forward to additional data from these studies, as we further characterize the utility of our agents in various breast cancer settings."
Information on the four abstracts:
Abstract Title: An Update to a Phase I Trial of CFI-402257, an oral TTK Inhibitor, in Patients with Advanced Solid Tumors with HER2-Negative Breast Cancer Expansion Cohorts
Abstract Title: CCTG IND.236: A Phase 1b Trial of Combined CFI-402257 and Weekly Paclitaxel in Patients with HER2 Negative (HER2-) Advanced Breast Cancer (aBC)
Abstract Title: CCTG IND.237: A phase II study of CFI-400945 in patients with advanced/metastatic HER2-negative breast cancer
Abstract Title: CCTG IND.239: A Phase 2 Study of Combined CFI-400945 and Durvalumab in Patients with Advanced